Proteomic Stroke Research
Thermo Fisher Scientific has announced the initial findings of stroke research conducted by its Biomarker Research Initiatives in Mass Spectrometry (BRIMS) centre in collaboration with Massachusetts General Hospital (MGH), Harvard University. According to the company, the research provides potentially significant insight into patent foramen ovale (PFO) and its connection with strokes.
Thermo Fisher Scientific has announced the initial findings of stroke research conducted by its Biomarker Research Initiatives in Mass Spectrometry (BRIMS) centre in collaboration with Massachusetts General Hospital (MGH), Harvard University. According to the company, the research provides potentially significant insight into patent foramen ovale (PFO) and its connection with strokes.
PFO is a congenital heart abnormality that leaves a passage open between the left and right sides of the heart, enabling blood clots to travel from the leg to the brain. The collaborative research has provided scientists with MS data, from which potential biomarkers have been identified. If confirmed, these may be useful in helping doctors to select the most appropriate treatment for individual PFO stroke patients.
The collaboration has also led to insights in the understanding of tissue plasminogen activator (tPA) in stroke treatment. tPA is a drug that can only be safely administered within a very short time after stroke symptoms occur. The treatment, which works by dissolving blood clots, has proven highly effective but only 5% of patients fit the criteria within which it is safe to administer tPA. Through the use of proteomics workflows, the data may someday help identify a wider scope of patients who might benefit from tPA.
This story originally appeared in The Column. Click here to view that issue.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
